Efficacy and Safety of Paromomycin for Visceral Leishmaniasis: A Systematic Review

Table 4

Nonserious adverse events reported.

Authors		Ear and labyrinth disorders	GI disorders	General disorders and administration site conditions	Infections and infestations	Musculoskeletal and connective disorders	Investigations	Nervous system disorders	Psychiatric disorders	Respiratory, thoracic and mediastinal disorders	Skin and subcutaneous tissue disorders
Hassan et al. [18]		0	0	0	0	0	0	0	0	0	0
Hailu et al. [16]		0	6	19	8	0	24	5	0	2	1
Jamil et al. [19]		1	6	26	3	1	0	1	1	2	5
Jha et al. [20]		2	1	0	0	0	0	0	0	0	0
Musa et al. [21]	20 mg/kg/day	3	1	14	1	0	0	0	0	0	1
	15 mg/kg/day	4	0	16	1	0	2	0	0	1	4
Sinha et al. [22]		0	0	49	1	0	484	0	0	0	1
Sundar et al. [1]		3	3	284	0	0	43	0	0	0	0
Sundar et al. [23]		0	0	145	0	0	138	0	0	0	0